Ro60-0213 (Org 35032) is a drug developed by Hoffmann–La Roche, which acts as a potent and selective agonist for the 5-HT2C serotonin receptor, with more than 100x selectivity over other closely related serotonin receptor subtypes, and little or no affinity at other receptors. It was developed as a potential antidepressant,[1] but was discontinued from clinical development at an early stage due to toxicity concerns.[2] However the high selectivity of Ro60-0213 for 5-HT2C makes it of continued interest for research into serotonin receptors.[3]
Identifiers | |
---|---|
| |
PubChem CID |
|
ChemSpider |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C15H18N2O |
Molar mass | 242.322 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |